Login
About Alexion
Our Leadership
Our Partnerships
Our Ethical Standards
Our History
Patient Focus
Advocacy
Patient Stories
Products
Soliris
®
PNH
aHUS
Strensiq
®
Kanuma
®
Research & Development
Our Pipeline
Development Programs
Investigator-Sponsored Research
Discovery Partnerships
Responsibility
Global Access to Medicines Policy
Main Menu
Careers
Job Opportunities
Why Choose Alexion
Culture
Compensation & Benefits
Work/Life Balance
Health & Wellness
Financial Security
Recognition & Rewards
Personal Growth & Development
Professional Development
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Select a Country
Investors
News
Contact
Search for:
North America
Canada
United States
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
United Kingdom
Asia Pacific
Australia
China
India
Japan
About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Home
»
Newsroom
»
Press Releases
Press Releases
Press Releases
Filter by Category
All Press Releases
Company Releases
Company Statements
Financial Releases
Product Releases
Sort by Year
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Media
Inquiries
Media
Materials
Email
Alerts
Press Releases
Search:
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 18, 2019
HTML
PDF
Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress
June 14, 2019
HTML
PDF
Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
May 13, 2019
HTML
PDF
Alexion to Present at the UBS Global Healthcare Conference
May 13, 2019
HTML
PDF
New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
May 3, 2019
HTML
PDF
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
April 26, 2019
HTML
PDF
Alexion Reports First Quarter 2019 Results
April 25, 2019
HTML
PDF
Alexion to Report First Quarter Results on Thursday, April 25, 2019
April 12, 2019
HTML
PDF
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
March 20, 2019
HTML
PDF
Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
March 20, 2019
HTML
PDF
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
